31 -8 (82) 2025 - Khamzaev K.A., Fayzakhmatova F.O. - EFFECTIVENESS OF TREATMENT OF STEROID-SENSITIVE NEPHROTIC SYNDROME IN CHILDREN WITH RITUXIMAB

EFFECTIVENESS OF TREATMENT OF STEROID-SENSITIVE NEPHROTIC SYNDROME IN CHILDREN WITH RITUXIMAB

Khamzaev K.A. - Tashkent State Medical University

Fayzakhmatova F.O. - National Children's Medical Center

Resume

Although with treatment of nephrotic syndrome in about 70% of children, remission occurs after treatment with prednisolone, but after discontinuation of treatment, relapses are noted in children. The results obtained by us showed the high effectiveness of using the monoclonal antibody rituximab in the treatment of steroid-sensitive nephrotic syndrome in children. In our study, in 68 (80%) children, it was possible to achieve long-term remission of the nephrotic syndrome due to repeated administration of rituximab every 6 months. Repeated prophylactic infusions of rituximab limited the duration of remission after 6, 12, or 18 months. Despite these limitations, we observed positive effects of Rituximab in children with NS, such as prolonged remission, achievement of children's growth and development.

Keywords: nephrotic syndrome, prednisolone, relapses, rituximab, remission of nephrotic syndrome.

First page

174

Last page

177

For citation:Khamzaev K.A., Fayzakhmatova F.O. - EFFECTIVENESS OF TREATMENT OF STEROID-SENSITIVE NEPHROTIC SYNDROME IN CHILDREN WITH RITUXIMAB//New Day in Medicine 8(82)2025 174-177 https://newdayworldmedicine.com/en/new_day_medicine/8-82-2025

List of References

1. Trautmann A, Boyer O, Hodson E, et al. IPNA clinical practice recommendations for the diagnosis and management of children with steroid-sensitive nephrotic syndrome. Pediatr Nephrol. 2023;38:877–919. https://doi.org/10.1007/s00467-022-05739-3
2. Schijvens AM, Teeninga N, Dorresteijn EM, Teerenstra S, Webb NJ, Schreuder MF. Steroid treatment for the first episode of childhood nephrotic syndrome: comparison of the and 12 weeks regimen using an individual patient data meta-analysis. Eur J Pediatr. 2021;180:2849–2859. https://doi.org/10.1007/s00431-021-04035-w
3. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021;100:S1–S276. https://doi.org/10.1016/j.kint.2021.05.021.
4. Zotta, F.; Vivarelli, M.; Emma, F. Update on the treatment of steroid-sensitive nephrotic syndrome. Pediatr. Nephrol. 2022, 37, 303–314.
5. Iijima K, Sako M, Nozu K (2017) Rituximab for nephrotic syndrome in children. Clin Exp Nephrol 21(2):193–202
6. Larkins NG, Liu ID, Willis NS, Craig JC, Hodson EM (2020) Non-corticosteroid immunosuppressive medications for steroid-sensitive nephrotic syndrome in children. Cochrane Database Syst Rev 4:CD002290.
7. Hladunewich MA, Beanlands H, Herreshoff E, Troost JP, Maione M, Trachtman H, Poulton C, Nachman P, Modes MM, Hailperin M, Pitter R, Gipson DS (2017) Provider perspectives on treatment decision-making in nephrotic syndrome. Nephrol Dial Transplant 32: i106–i114.
8. Deschênes G, Vivarelli M, Peruzzi L (2017) Variability of diagnostic criteria and treatment of idiopathic nephrotic syndrome across European countries. Eur J Pediatr 176:647–654.
9. Ito S, Kamei K, Ogura M, Udagawa T, Fujinaga S, Saito M, et al. Survey of rituximab treatment for childhood-onset refractory nephrotic syndrome. Pediatr Nephrol. 2013;28(2):257–64.
10. Sinha A, Bagga A. Rituximab therapy in nephrotic syndrome: implications for patients’ management. Nat Rev Nephrol. 2013;9(3):154.

    file

    download